developed a bispecific T-cell engager (CD19-ENG)-based CAR-NK therapy capable of dual targeting CD22+ B-cell leukemia while redirecting T-cells to eliminate CD19+ malignant B-cells, effectively preventing tumor immune evasion and augmenting cytotoxic activity (104). The gene discussed is CD19; the disease is neoplasm.